Evidence map›Paper›PMID 40011519›Full record

Observational studyScientific reports2025

Post-COVID-19 condition in prospective inpatient and outpatient cohorts.

Antti Hurme, Arja Viinanen, Johanna Teräsjärvi, Pinja Jalkanen, Thijs Feuth, Eliisa Löyttyniemi, Tytti Vuorinen, Anu Kantele, Jarmo Oksi, Qiushui He and 1 more

Abstract readObservational Study
In one paragraph

Observational study in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Antti HurmeDepartment of Infectious Diseases, Turku University Hospital and University of Turku, Turku, Finland. antahu@utu.fi.
Arja ViinanenDepartment of Pulmonary Diseases, Turku University Hospital and Department of Pulmonary Diseases and Clinical Allergology University of Turku, Turku, Finland.
Johanna TeräsjärviInstitute of Biomedicine, University of Turku, Turku, Finland.
Pinja JalkanenInstitute of Biomedicine, University of Turku, Turku, Finland.
Thijs FeuthDepartment of Pulmonary Diseases, Turku University Hospital and Department of Pulmonary Diseases and Clinical Allergology University of Turku, Turku, Finland.
Eliisa LöyttyniemiDepartment of Biostatistics, University of Turku and Turku University Hospital, Turku, Finland.
Tytti VuorinenInstitute of Biomedicine, University of Turku, Turku, Finland.
Anu KanteleMeilahti Vaccine Research Center, MeVac, Department of Infectious Diseases, Helsinki University Hospital and University of Helsinki, Helsinki, Finland.
Jarmo OksiDepartment of Infectious Diseases, Turku University Hospital and University of Turku, Turku, Finland.
Qiushui HeInstitute of Biomedicine, University of Turku, Turku, Finland.
Ilkka JulkunenInstitute of Biomedicine, University of Turku, Turku, Finland.

Funding

Jane ja Aatos Erkon Säätiö 3067-84b53Jane ja Aatos Erkon Säätiö 5360-cc2fcResearch Council of Finland 337530Sigrid Juséliuksen Säätiö 240045Tampereen Tuberkuloosisäätiö 26006205
6 · The paper itself

Abstract

Viral persistence, immune dysregulation, hypocortisolism, and pulmonary tissue damage from acute infection are proposed as pathogenic mechanisms underlying post-COVID-19 condition (PCC). In this prospective observational study, we followed 62 COVID-19 inpatients and 53 COVID-19 outpatients for 24 months after the infection. During this period, we assessed prolonged symptoms, lung function, and a set of immunological markers and a proportion of the patient group was assessed with computed tomography three months post-infection. The prevalence of PCC, as assessed by four medical specialists, decreased from 51% at three months to 18% at 24 months. Risk factors included the severity of the acute infection and comorbidities of obstructive sleep apnea or obesity. Patients with PCC had higher serum levels of anti-SARS-CoV-2 S1 and N protein antibodies. In the whole group, spirometry results, orthostatic hypotension, or levels of soluble suppression of tumorigenicity 2, interleukin 6 (IL-6), high-sensitivity C-reactive protein (hs-CRP), or cortisol had no association with PCC. However, using symptom clusters, patients with cognitive problems had lower cortisol levels, while patients with ongoing respiratory or myalgic symptoms had higher levels of IL-6 and hs-CRP. However, more extensive studies with clustering are needed to validate these results.

Indexed as

COVID-19AdultAgedC-Reactive ProteinFemaleHumansInpatientsInterleukin-6MaleMiddle AgedOutpatientsProspective StudiesRisk FactorsSARS-CoV-2Sleep Apnea, ObstructiveC-Reactive ProteinInterleukin-6Anti-SARS-CoV-2 antibodiesCortisolIL-6InflammationLong COVIDPost-acute COVID-19 syndromeViral persistenceViral pneumonia

Identifiers

PMID40011519
PMCPMC11865615

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.